Rol' serotoninovykh retseptorov v motorno-evakuatornoy funktsii zheludochno-kishechnogo trakta


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

This article discusses the mechanisms of action of some neurohumoral substances on the motility of the gastrointestinal tract, including intestinal contractions. The first, the role of serotonin in the regulation of motor activity of the digestive tube is discussed. The comparative analysis of currently used serotoninergic drugs (tegaserod, prucalopride) affecting the motor activity of the esophagus, stomach and intestines is presented. The clinical manifestations of deficiency and an excess of serotonin in the human body, and ways for their correction are discussed.

Full Text

Restricted Access

About the authors

E. Yu Plotnikova

Email: eka-pl@rambler.ru

O. A Krasnov

References

  1. Medhus A.W., Sandstad O., Naslund E., at al. The influence of the migrating motor complex on the postprandial endocrine response. Scand. J. Gastroenterol. 1999; 34: 1012-18.
  2. Buchheit K.H., Engel G., Mutschler E., Richardson B. Study of the contractile effect of 5-hydroxytrypta-mine (5-HT) in the isolated longitudinal muscle strip from guinea-pig ileum. Evidence for two distinct release mechanisms. Naunyn Schmiedebergs Arch. Pharmacol. 1985; 329: 36-41.
  3. Kim D.Y., Camilleri M. Serotonin: a mediator of the brain-gut connection. Am. J. Gastroenterol. 2000; 95: 2698-709.
  4. Woollard D.J., Bornstein J.C., Furness J.B. Characterization of 5-HT receptors mediating contraction and relaxation of the longitudinal muscle of guinea-pig distal colon in vitro. Naunyn Schmiedebergs Arch. Pharmacol. 1994; 349: 455-62.
  5. Yamano M., Ito H., Miyata K. Species differences in the 5-hydroxytryptamine-induced contraction in the isolated distal ileum. Jpn. J. Pharmacol. 1997; 74: 267-74.
  6. De Maeyer J.H., Lefebvre R.A., Schuurkes J.A. 5-HT4 receptor agonists: similar but not the same. Neurogastroenterol. Motil. 2008; 20: 99-112.
  7. Hannon J., Hoyer D. Molecular biology of 5-HT receptors. Behav. Brain Res. 2008; 195: 198-213.
  8. Berger M., Gray J.A., Roth B.L. The expanded biology of serotonin. Annu. Rev. Med. 2009; 60: 355-66.
  9. Crowell M.D. Role of serotonin in the pathophysiology of the irritable bowel syndrome. Br. J. Pharmacol. 2004; 141: 1285-93.
  10. Gershon M.D. Plasticity in serotonin control mechanisms in the gut. Curr. Opin. Pharmacol. 2003; 3: 600-7.
  11. Bearcroft C.P., Perrett D., Farthing M.J. Postprandial plasma 5-hydroxytryptamine in diarrhoea predominant irritable bowel syndrome: a pilot study. Gut. 1998; 42: 42-6.
  12. Hansen M.B. Small intestinal manometry. Physiol. Res. 2002; 51: 541-56.
  13. Fishlock D.J., Parks A.G., Dewell J.V. Action of 5-hydroxytryptamine on the human stomach, duodenum, and jejunum in vitro. Gut. 1965; 6: 338-42.
  14. Hopkinson G.B., Hinsdale J., Jaffe B.M. Contraction of canine stomach and small bowel by intravenous administration of serotonin. A physiologic response? Scand. J. Gastroenterol. 1989; 24: 923-32.
  15. Hansen M.B., Gregersen H., Husebye E., Wallin L. Effect of serotonin and ondansetron on upper Gl manometry in healthy volunteers. Neurogastroenterol. Motil. 2000; 12: 281.
  16. Boerckxstaens G.E., Pelckmans P.A., Rampart M., at al. Pharmacological characterization of 5-hydroxytryptamine receptors in the canine terminal ileum and ileocolonic junction. J. Pharmacol. Exp. Ther. 1990; 254: 652-58.
  17. Albert E., Mikkelsen H.B., Larsen J.O., Jimenez M. Motility patterns and distribution of interstitial cells of Cajal and nitrergic neurons in the proximal, mid- and distal-colon of the rat. Neurogastroenterol. Motil. 2005; 17: 133-47.
  18. Sanders K.M. A case for interstitial cells of Cajal as pacemakers and mediators of neurotransmission in the gastrointestinal tract. Gastroenterology. 1996; 111: 492-515.
  19. Thomsen L., Robinson T.L., Lee J.C., at al. Interstitial cells of Cajal generate a rhythmic pacemaker current. Nat. Med. 1998; 4: 848-51.
  20. Park S.Y., Je H.D., Shim J.H., Sohn U.D. Characteristics of spontaneous contraction in the circular smooth muscles of cat ileum. Arch. Pharm. Res. 2010; 33: 159-65.
  21. Balestra B., Vicini R., Pastoris O., at al. 5-HT receptors and control of intestinal motility: expression and hierarchic role. Poster Session, Bologna, 2011.
  22. Read N.W., Gwee K.A. The importance of 5-hydroxytryptamine receptors in the gut. Pharmacol. Ther. 1994; 62 (1 -2): 159-73.
  23. Lucchelli A., Santagostino-Barbone M.G., Barbieri A., at al. The interaction of antidepressant drugs with central and peripheral (enteric) 5-HT3 and 5-HT4 receptors. Br. J. Pharmacol. 1995; 114(5): 1017-25.
  24. Ford A.C., Talley N.J., Schoenfeld P.S., Quigley E.M., Moayyedi P. Efficacy of antidepressants and psychological therapies in irritable bowel syndrome: systematic review and meta-analysis. Gut. 2009; 58(3): 367-78.
  25. Friedrich M., Grady S.E., Wall G.C. Effects of antidepressants in patients with irritable bowel syndrome and comorbid depression. Clin. Ther. 2010; 32(7): 1221-33.
  26. Chial H.J., Camilleri M., Burton D., at al. Selective effects of serotonergic psychoactive agents on gastrointestinal functions in health. Am. J. Physiol. Gastrointest. Liver Physiol. 2003; 284: G130-37.
  27. Turvill J.L., Connor P., Farthing M.J. The inhibition of cholera toxin-induced 5-HT release by the 5-HT(3) receptor antagonist, granisetron, in the rat. Br. J. Pharmacol. 2000; 130: 1031-36.
  28. Ruckebusch Y., Bardon T. Involvement of serotonergic mechanisms in initiation of small intestine cyclic motor events. Dig. Dis. Sci. 1984; 29: 520-27.
  29. Haus U., Spath M., Farber L. Spectrum of use and tolerability of 5-HT3 receptor antagonists. Scand. J. Rheumatol. Suppl. 2004; 119: 12-8.
  30. Ford A.C., Brandt. L.J., Young C., at al. Efficacy of 5-HT3 antagonists and 5-HT4 agonists in irritable bowel syndrome: Systematic review and metaanalysis. Am. J. Gastroenterol. 2009; 104: 1831 -43.
  31. US Food and Drug Administration. Glaxo Wellcome withdraws irritable bowel syndrome medication. FDA Consum. 2001; 35: 3.
  32. Johanson J.F., Drossman D.A., Panas R., Wahle A., Ueno R. Clinical trial: phase 2 study of lubiprostone for irritable bowel syndrome with constipation. Aliment. Pharmacol. 2008; 27: 685-96.
  33. Camilleri M., Kerstens R., Rykx A., Vandeplassche L. A Placebo-Controlled Trial of Prucalopride for Severe Chronic Constipation. N. Engl. J. Med. 2008; 358: 2344-54.
  34. Tack J. van Outryve M., Beyens G., Kerstens R., Vandeplassche L. Prucalopride (Resolor) in the treatment of severe chronic constipation in patients dissatisfied with laxatives. Gut. 2009; 58: 357-65.
  35. Quigley E.M., Vandeplassche L., Kerstens R., Ausma J. Clinical trial: the efficacy, impact on quality of life, and safety and tolerability of prucalopride in severe chronic constipation - a 12-week, randomized, double-blind, placebo-controlled study. Aliment. Pharmacol. Ther. 2009; 29: 315-28.
  36. http://www.pbs.gov.au/industry/listing/elements/pbac-meetings/psd/2012-7/prucalopride.pdf.
  37. Cinca R., Chera D., Gruss H.J., Halphen M. Randomised clinical trial: macrogol/PEG 3350 + electrolytes versus prucalopride in the treatment of chronic constipation - a comparison in a controlled environment. Aliment. Pharmacol. Ther. 2013; 37(9): 876-86.
  38. Буров Н.Е. Тошнота и рвота в клинической практике (этиология, патогенез, профилактика и лечение). Российский медицинский журнал. 2002; 16: 390-95.
  39. Баринов Э.Ф., Сулаева О.Н. Роль серотонина в физиологии и патологии желудочно-кишечного тракта. РЖГГК. 2012; 21(2): 4-13.
  40. Ашмарин И.П., Ещенко Н.Д., Каразеева Е.П. Нейрохимия в таблицах и схемах. «Экзамен», М., 2007. 143 с.
  41. Palczewski K., Kiser P.D. As good as chocolate. Science. 2013; 340: 562-63.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies